Brain Tumor Treatment by Targeting TUG1, a Gene That Controls Replication Stress

Researchers discovered the mechanism of interaction among TUG1 (red), R-loops (green), and another protein (blue) in cancer cells, which provides a key to therapeutic applications. 
(Credit: Yutaka Kondo, Nagoya University).

A new study has unraveled a crucial link between how cancer cells cope with replication stress and the role of taurine upregulated gene 1 (TUG1). By targeting TUG1 with a drug, the researchers were able to control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors such as glioblastomas. “These findings have the potential to be translated into therapeutic applications, as TUG1 is highly expressed in glioblastoma,” said lead researcher Professor Yutaka Suzuki. “In this study, we successfully developed a therapeutic drug named TUG1-DDS, which selectively targets TUG1. It significantly suppressed tumor growth and improved survival, especially when administered in combination with the standard treatment of temozolomide. Therefore, it is a potentially effective therapeutic agent for treating glioblastoma.” 

Login Or Register To Read Full Story